Heparin-associated thrombocytopenia in 24401 patients with venous thromboembolism: Findings from the RIETE Registry

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 9, 2011, Pages 1761-1768

  Falvo, N ^a   Bonithon Kopp, C ^a   Rivron Guillot, K ^b,c,d   Todoli, J A ^e   Jimenez Gil M ^f   Di Micco, P ^g   Monreal, M ^h  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d HÔPITAL NORD   (France)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL GENERAL DE ELDA   (Spain)

^g Ospedale Buonconsiglio Fatebenefratelli   (Italy)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Heparin; Prognosis; Thrombocytopenia; Thromboembolic disease

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; DISEASE DURATION; FEMALE; FOLLOW UP; GENDER; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

AGED; COHORT STUDIES; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SEX FACTORS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 80052395379     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04402.x     Document Type: Article

References (19)

1. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21: 589-607.
2. Wallis DE, Lewis BE, Messmore H, Wehrmacher WH. Heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1998; 4: 160-3.
3. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-5.
4. Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin ?tul> or unfractionated heparin: a meta analysis. Chest 2007; 132: 1131-9.
5. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-8.
6. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost, 2007; 5: 1666-73.
7. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
8. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2004.
9. Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009; 122: 919-30.
10. Merli GJ. Duration of deep vein thrombosis and pulmonary embolism prophylaxis after joint arthroplasty. Med Clin North Am 2001; 85: 1101-7.
11. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160: 229-36.
12. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
13. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337: 663-9.
14. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
15. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937-41.
16. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004; 164: 361-9.
17. Crespo EM, Oliveira GB, Honeycutt EF, Becker RC, Berger PB, Moliterno DJ, Anstrom KJ, Abrams CS, Kleiman NS, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Granger CB, Ohman EM, CATCH Registry Investigators. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J. 2009;157:651-7.
18. Oliveira GBF, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin. Arch Intern Med 2008; 168: 94-102.
19. Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost 2008; 100: 1130-5.